DemeRx IB, an atai Life Sciences (atai) platform company focused on developing ibogaine for the treatment of opioid use disorder (OUD), announced the company has approval from the UK Medicines and Healthcare products Regulatory Agency (MHRA) to ...
The UK Medicines and Healthcare products Regulatory Agency (MHRA) has approved the launch of a Phase I/IIa trial of DemeRx and atai Life Sciences’ ibogaine HCl (DMX-1002) for the treatment of opioid use disorder (OUD).